AIM ImmunoTech

AIM lacks recurring revenue and its outlook is binary around an exploratory, single‑center Phase 2 trial (DURIPANC) aiming to assess clinical benefit rate at six months post‑initiation. Timelines are well signposted, but outcome predictability is low, external control benchmarks are shifting, and any subsequent Phase 3 path is unproven.

Approval of daraxonrasib changes the standard of care context and may shift trial designs and payer expectations. Overall visibility into multi‑year cash generation is minimal.